Bergqvist M[au] - Search Results

Year	Number of Results
1963	1
1992	1
1993	1
1995	1
1996	2
1998	5
1999	2
2000	2
2001	3
2002	3
2003	4
2004	8
2005	4
2006	6
2007	3
2008	5
2009	4
2010	9
2011	6
2012	10
2013	11
2014	10
2015	8
2016	5
2017	11
2018	9
2019	7
2020	7
2021	6
2022	13
2023	2

1

CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis.

Lugano R, Vemuri K, Yu D, Bergqvist M, Smits A, Essand M, Johansson S, Dejana E, Dimberg A. Lugano R, et al. Among authors: bergqvist m. J Clin Invest. 2018 Aug 1;128(8):3280-3297. doi: 10.1172/JCI97459. Epub 2018 Jun 25. J Clin Invest. 2018. PMID: 29763414 Free PMC article.

2

ELTD1 deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma.

Huang H, Georganaki M, Conze LL, Laviña B, van Hooren L, Vemuri K, van de Walle T, Ramachandran M, Zhang L, Pontén F, Bergqvist M, Smits A, Betsholtz C, Dejana E, Magnusson PU, He L, Lugano R, Dimberg A. Huang H, et al. Among authors: bergqvist m. Neuro Oncol. 2022 Mar 12;24(3):398-411. doi: 10.1093/neuonc/noab181. Neuro Oncol. 2022. PMID: 34347079 Free PMC article.

3

Reply to Assoc. Prof. Kocak.

Willén L, Berglund A, Bergström S, Isaksson J, Bergqvist M, Wagenius G, Lambe M. Willén L, et al. Among authors: bergqvist m. Acta Oncol. 2022 Mar;61(3):320. doi: 10.1080/0284186X.2021.2023216. Epub 2022 Jan 11. Acta Oncol. 2022. PMID: 35012418 No abstract available.

4

The Use of Complementary and Alternative Medicine in Scandinavia.

Nilsson J, Källman M, Östlund U, Holgersson G, Bergqvist M, Bergström S. Nilsson J, et al. Among authors: bergqvist m. Anticancer Res. 2016 Jul;36(7):3243-51. Anticancer Res. 2016. PMID: 27354580 Review.

5

Esophageal cancer: current and emerging therapy modalities.

Ekman S, Dreilich M, Lennartsson J, Wallner B, Brattström D, Sundbom M, Bergqvist M. Ekman S, et al. Among authors: bergqvist m. Expert Rev Anticancer Ther. 2008 Sep;8(9):1433-48. doi: 10.1586/14737140.8.9.1433. Expert Rev Anticancer Ther. 2008. PMID: 18759695 Review.

6

Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review.

Blomberg C, Nilsson J, Holgersson G, Edlund P, Bergqvist M, Adwall L, Ekman S, Brattström D, Bergström S. Blomberg C, et al. Among authors: bergqvist m. Anticancer Res. 2015 May;35(5):2493-501. Anticancer Res. 2015. PMID: 25964522 Review.

7

End-of-life care: Where do cancer patients want to die? A systematic review.

Nilsson J, Blomberg C, Holgersson G, Carlsson T, Bergqvist M, Bergström S. Nilsson J, et al. Among authors: bergqvist m. Asia Pac J Clin Oncol. 2017 Dec;13(6):356-364. doi: 10.1111/ajco.12678. Epub 2017 Mar 13. Asia Pac J Clin Oncol. 2017. PMID: 28294576 Review.

8

Activation of growth factor receptors in esophageal cancer--implications for therapy.

Ekman S, Bergqvist M, Heldin CH, Lennartsson J. Ekman S, et al. Among authors: bergqvist m. Oncologist. 2007 Oct;12(10):1165-77. doi: 10.1634/theoncologist.12-10-1165. Oncologist. 2007. PMID: 17962610 Free article. Review.

9

Dynamics of plasma thymidine kinase activity in metastatic melanoma reflects immune checkpoint inhibitor efficacy.

Costa Svedman F, Jalsenius M, Grozman V, Bergqvist M, Söderdahl F, Rotstein S, Ny L, Egyhazi Brage S, Helgadottir H. Costa Svedman F, et al. Among authors: bergqvist m. Acta Oncol. 2022 Sep;61(9):1116-1120. doi: 10.1080/0284186X.2022.2121615. Epub 2022 Sep 9. Acta Oncol. 2022. PMID: 36083107 No abstract available.

10

Hsp90 as a therapeutic target in patients with oesophageal carcinoma.

Ekman S, Bergqvist M, Tell R, Bergström S, Lennartsson J. Ekman S, et al. Among authors: bergqvist m. Expert Opin Ther Targets. 2010 Mar;14(3):317-28. doi: 10.1517/14728221003621278. Expert Opin Ther Targets. 2010. PMID: 20148718 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results